10 Key Takeaway’s from J.P. Morgan's Mid 2026 Healthcare markets outlook

Healthcare markets outlook: A “dynamic” landscape ripe for M&A deals and cross-border partnerships
June 26, 2026. In spite of macro uncertainty, dealmaking in healthcare remains active, with capital following differentiated innovation, scalable platforms, resilient business models and, of course, AI.

Here are 10 key points from J.P. Morgan's mid-year 2026 healthcare outlook:

1.     M&A and capital markets remain robust despite macro uncertainty, with capital flowing toward differentiated innovation, scalable platforms, resilient business models and AI. Strategic urgency — driven by patent cliffs, pipeline gaps and strong pharma balance sheets — is the core fuel.

2.     Biopharma/biotech is leading dealmaking, with companies making strategic acquisitions to replenish pipelines. JPM cites Gilead's ~$5bn acquisition of Tubulis (next-gen antibody-drug conjugates) — the largest-ever European private, clinical-stage oncology sell-side deal.

3.     Megadeals are back. Sun Pharma's $11.75bn acquisition of Organon was the year's largest biopharma deal, pairing two financially strong companies to expand Sun's Innovative Medicines business.

4.     Financial sponsors are increasingly active. Thoreau's acquisition of Ensemble (revenue-cycle managed services) was the largest sponsor-to-sponsor transaction globally across all industries in 2026.

5.     Cross-border activity is rising as companies reach further afield for innovation — e.g., GN Store Nord's hearing division merging with Italy's Amplifon, and Italy's Angelini Pharma acquiring US-based Catalyst Pharmaceuticals ($4.1bn) in rare neuromuscular diseases.

6.     China is emerging as an innovation hub. JPM highlights rapid emergence of high-quality, cost-effective Chinese innovation pipelines, driving more out-licensing and partnership models with global pharma.

7.     AI has shifted from experimentation to a real driver of capital allocation, becoming a core component of product strategy across diagnostics, imaging, clinical decision support, patient monitoring and precision medicine. The question has moved from "can AI create value" to "how fast can companies incorporate it."

8.     Companies are buying AI rather than building it — acquiring AI-native businesses for proprietary data, algorithms and capabilities (e.g., CareDX/Naveris, Waystar/Iodine Software, Performant/Machinify). AI is also reaching back-office functions like claims, reimbursement and revenue-cycle automation.

9.     A more complex policy and regulatory environment is reshaping strategy. Facing pricing pressure and market-access challenges, companies use M&A for execution certainty (e.g., Alkermes/Avadel) while taking a disciplined approach to portfolio management via divestitures, carve-outs and take-privates (e.g., Baxter divesting Vantive Kidney Care, Select Medical going private).

10.  Supply chain resilience is a strategic priority. Tariffs, energy costs and other shocks are pushing companies to diversify sourcing, invest in advanced manufacturing and integrate vertically — aligned with JPM's $1.5 trillion, 10-year Security and Resiliency Initiative, of which pharma and healthtech form an entire pillar.

Source: https://www.jpmorgan.com/insights/banking/investment-banking/healthcare-mid-year-outlook